Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETFTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs State Street SPDR S&P Biotech ETF — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.69, while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.

SJNKXBI
Sector
Sector/ThematicBroad Market / Factor
52-Week High
$25.63$169.55
52-Week Low
$24.67$93.43

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF

SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.70 with minimal daily movement (-0.04%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral. The ETF continues its regular dividend distributions, with recent payments of $0.14-0.15 per share. Institutional activity shows mixed sentiment with some firms reducing positions.

The outlook remains cautious given the bearish technical signals and institutional selling pressure. While the ETF provides consistent dividend income, high-yield bond markets face headwinds from potential yield increases and economic uncertainty. Investors should weigh the income generation against credit risk exposure in the current market environment.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF

SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.

Read more on SJNK

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI